Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;52(3):571-572.
doi: 10.1111/apt.15893. Epub 2020 Jun 25.

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply

Carlos Taxonera  1 , Iñigo Sagastagoitia  2 , Cristina Alba  1 , Norberto Mañas  1 , David Olivares  1 , Enrique Rey  1
Affiliations
Comment

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply

Carlos Taxonera et al. Aliment Pharmacol Ther. 2020 Aug.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al an Garg et al papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15814.

PubMed Disclaimer

Comment on

References

    1. Garg M, Royce SG, Lubel JS. Letter: intestinal inflammation, COVID‐19 and gastrointestinal ACE2 – exploring RAS inhibitors. Aliment Pharmacol Ther. 2020;52:569‐570. - PMC - PubMed
    1. Taxonera C, Sagastagoitia I, Alba C, et al. 2019 Novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020. May 2. doi: 10.1111/apt.15804. Online ahead of print. - DOI - PMC - PubMed
    1. Garg M, Christensen B, Lubel JS. Letter: gastrointestinal ACE2, COVID‐19 and IBD—opportunity in the face of tragedy? Gastroenterology. 2020. S0016–5085(20)30570–9. Online ahead of print. - PMC - PubMed
    1. Annweiler C, Cao Z, Wu Y, et al. Counter‐regulatory 'Renin‐Angiotensin' system‐based candidate drugs to treat COVID‐19 diseases in SARS‐CoV‐2‐infected patients. Infect Disord Drug Targets. 2020. May 17. 10.2174/1871526520666200518073329. Online ahead of print. - DOI - PubMed
    1. Antwi‐Amoabeng D, Kanji Z, Ford B, et al. Clinical outcomes in COVID‐19 patients treated with tocilizumab: an individual patient data systematic review. J Med Virol. 2020. May 21. 10.1002/jmv.26038. Online ahead of print. - DOI - PMC - PubMed

LinkOut - more resources